DexCom forward PE DXCM

Share price divided by analysts' consensus earnings for the next twelve months, since 2018.

Today, Oct 23, 2026: 27.7×
8-year median: 102×
Against its 8-year history: 6th; percentile: 0 is its lowest day, 100 its highest
8-year range: 22.8× to 412×
Peer median: 16.8×

DexCom's forward PE is 27.7× as of Oct 23, 2026.

That is below its 8-year median of 102×, lower than on 94% of days in the last 8 years.

Over that time it ranged from 22.8× in May 2026 to 412× in Jan 2019.

The median for 9 medical device stocks of a similar size is 16.8×.

Forward PE over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	27.7×	22.8×	32.8×
2025	28.1×	22.9×	48.6×
2024	43.9×	38.0×	88.5×
2023	81.6×	53.4×	117×
2022	115×	81.2×	160×
2021	173×	134×	208×
2020	159×	102×	199×
2019	117×	101×	412×
2018	326×	298×	412×

Against its peers

Companies in Medical - Devices nearest DexCom's size, closest first, today.

Company	Forward PE
DXCMDexCom	27.7×
GEHCGE HealthCare Technologies	13.8×
ZBHZimmer Biomet	n/m
EWEdwards Lifesciences	28.3×
BSXBoston Scientific	14.1×
SYKStryker	19.3×
MDTMedtronic	15.9×
ABTAbbott Laboratories	17.7×
LIVNLivaNova	n/m
ITGRInteger	n/m
Peer median	16.8×

Where DexCom ranks

#40of 51Healthcare stocks with the lowest forward PE

What the forward PE tells you

Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.

Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.

More on DexCom

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.